by Evelyn Ma | Sep 8, 2026 | Blog
Why Kinase Selectivity Demands Multiple Assay Formats The human kinome comprises more than 500 kinases sharing a conserved ATP-binding pocket and high structural homology. This conservation is the central obstacle in kinase drug discovery: a compound potent against...
by Evelyn Ma | Aug 1, 2026 | Blog
Participants: Haiching Ma, PhD (Founder & CSO, Reaction Biology), Jason Amsbaugh, MBA (CEO, Samba Scientific), Trent Carrier, PhD, MBA (CEO, Carolina Molecular) Overview Reaction Biology is celebrating its 25th anniversary this year, having grown from a small...
by Evelyn Ma | Jul 27, 2026 | Newsletter
Headlines In This Issue Scientific Spotlight Our biochemical kinase platform, including HotSpot™ and ³³PanQinase™, comprise the largest kinase library in the industry. Featured Research Two new studies on kinase polypharmacology: a Nature Biotechnology paper...
by Evelyn Ma | May 14, 2026 | Newsletter
Headlines In This Issue Scientific Spotlight: Immuno-Oncology Explore how tumor-associated macrophages influence therapeutic outcomes and why comprehensive preclinical models are essential for IO drug development Featured Research: AACR 2026 Poster New data on...
by Evelyn Ma | Mar 26, 2026 | Blog
Over 100 kinase inhibitors have now been approved by the FDA, transforming the treatment of cancer and other diseases.¹ Yet despite this progress, a key question remains underexplored: can these drugs be repurposed to target newly identified oncogenic kinase variants...
